Phenylephrine/ketorolac

Last updated

Phenylephrine/ketorolac
Combination of
Phenylephrine Alpha-1 adrenergic receptor agonist
Ketorolac Nonsteroidal anti-inflammatory
Clinical data
Trade names Omidria
AHFS/Drugs.com Monograph
License data
Routes of
administration 		Intraocular
ATC code
Legal status
Legal status
Identifiers
KEGG

Phenylephrine/ketorolac, sold under the brand name Omidria, is a combination drug used during cataract surgery [3] or intraocular lens replacement to prevent intraoperative miosis and to reduce postoperative pain. [1] It contains phenylephrine and ketorolac. [1]

Phenylephrine/ketorolac was approved for medical use in the United States in May 2014, [4] and in the European Union in July 2015. [2]

References

  1. 1 2 3 "Omidria- phenylephrine and ketorolac injection, solution, concentrate". DailyMed. 11 December 2017. Retrieved 17 April 2020.
  2. 1 2 "Omidria EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 17 April 2020.
  3. ↑ Lawuyi LE, Gurbaxani A (2015). "The clinical utility of new combination phenylephrine/ketorolac injection in cataract surgery". Clinical Ophthalmology. 9. Auckland, N.Z.: 1249–54. doi: 10.2147/OPTH.S72321 . PMC   4506037 . PMID   26203214.
  4. ↑ "Drug Approval Package: Omidria (phenylephrine and ketorolac) Injection NDA #205388". U.S. Food and Drug Administration (FDA). 9 December 2014. Archived from the original on 16 April 2015. Retrieved 17 April 2020.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.